前苏联专利SU791237A3 Method of preparing derivatives of thiazole-2-oxamic acid or their salts

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Compounds of the formula <IMAGE> wherein R1 is hydrogen or alkyl of 1 to 4 carbon atoms; R2 is hydrogen, methyl or carboxyl; and A is pyridyl, benzodioxanyl or <IMAGE> where R3, R4 and R5, which may be identical to or different from each other, are each hydrogen, hydroxyl, alkoxy, alkyl, halogen, carboxyalkyl or nitro, or one of R3, R4 or R5 is dialkylamino, carboxamido, morpholino, piperidino, hydroxy-piperidino, cyano or phenyl; non-toxic salts thereof formed with an inorganic base when R1 is hydrogen and/or R2 is carboxyl; and non-toxic addition salts thereof formed with an organic base when R1 is hydrogen. The compounds are useful as antiallergics.
公开号:SU791237A3
申请号:SU792776204
申请日:1979-06-20
公开日:1980-12-23
发明作者:Карл Гесс Фридрих；Брайэн Стюарт Петрик；Томас Оливер Джеймс
申请人:К.Х.Берингер Зон (Фирма)；
IPC主号:

专利说明:

by a method of preparing compounds of general formula 1 or their salts, which is that a 2-amino thiaol jo 6meft of the formula 11 N where Rj and A have the indicated values are reacted with oxalic acid derivative of the formula III with o-tg-, where R - alkyl with 1-4 carbon atoms of the R. alkoxy group with 1-4 carbon atoms or a chlorine atom, followed, if necessary, by saponification of the ester obtained, and the desired product is isolated in free form or as a salt. The starting compound of general formula G1 or its acid addition salt is dissolved in an inert solvent or suspended and added dropwise to an oxaloyl derivative. Benzene, toluene, xylene, alcohol or tetrahydrofuran, which are inert to the reactant compounds, are used as a solvent, respectively, as a suspending agent. An organic base, for example, pyridine or tr ethylamine, is added to bind the resulting acid. Since the reaction is highly exothermic, oxalic acid derivative is added slowly, if necessary with cooling, the reaction is completed in 30-180 minutes. Since almost all thiazole compounds are difficult to dissolve, it is recommended that the reaction mixture be left under stirring, for example overnight, before separation. The separation is carried out in a known manner by evaporation of the solvent, extraction of the residue under a suitable solvent or mixture of solvents, for example, ether, acetic ether, chloroform or hexane, purification of the extract, evaporation of the solvent and recrystallization. In some cases, purification is carried out using column chromatography. If it is necessary to obtain the target product of the general formula 1, where R is a hydrogen atom, the ether group is cleaved off. This is accomplished by hydrolysis in the presence of a catalyst, a basic or acidic agent, for example, a strong base, such as sodium hydroxide or calcium, or a mineral acid. such as salt, chamois or phosphorus. Compounds of general formula I, where R is a hydrogen atom, can be converted into their salts, if necessary. For this purpose, the acid is dissolved in water or suspended and the necessary base is added until a pH of 7 is obtained. The preparation of thiazole-2-oxamic acid derivatives is illustrated by examples. PRI me R -1. Ethyl ester of 4- (2-methoxyphenyl) -thiazole-2-oxamic acid. 2.9 g of ethyl oxalyl chloride are added dropwise to the suspension from b g of 2-aminr-4- (2-methoxyphenyl) -thiazole hydroiodide in pyridine and the mixture is stirred overnight at room temperature. After evaporation of the reaction mixture to dryness, the residue is treated with sodium bicarbonate solution and extracted several times with ethyl ether. The combined extracts are washed three times with water and once with brine, and then dried over MgSOi. After evaporation to dryness and recrystallization from ethanol, the title compound is obtained in a yield of 4.2 g (70%). M.p. 118-122 ° C. The 2-amino-4- (2-methoxyphenyl} -thiazole hydroiodide used as starting material is obtained as follows: 15 g of o-methoxyacetophenone and 15.2 g of urea are thoroughly mixed in a flask of artificial resin. To this mixture is added in small portions 27.7 g of iodine.After the addition is complete, the reaction mixture is heated overnight in an oil bath to 100 ° C. After cooling, 50 ml of methanol is added, then 400 to 500 ml of water, the solid mass is ground in a mortar, the suspension is filtered, washed water, a small amount of ethyl alcohol and ether and then dried. 27.7 g (83%) of the title compound are obtained, which is used as a starting product without further purification. Example 2. 4- (2, 5-dimethoxyphenyl) -thiazole-2-oxamic acid ethyl ester To a solution of 3 g of 2-amino-4- (2, 5-dimethoxyphenyl) -thiazole in dry pyridine, 2 g of oxalic acid ethyl ester chloride in 35 ml of dry pyridine are added dropwise. After the addition is complete, the mixture is stirred for 2.5 h. and during this time the progress of the reaction is observed by thin layer chromatography. At the end of the reaction, the mixture is poured into ice water, the resulting precipitate is filtered, washed with water and listened to. After recrystallization from ethanol
And n-hexane / chloroform is obtained 2, Ug of the title compound with mp 143144 ° C.
Example 3. 4- (Gpyridyl- (2) -thiaeol-2-oxamic acid ethyl ester.
A solution of 1 g of 2-amino-4- {pyridyl- (2) -thiazole in 25 ml of diethyloxalate is heated to 125 ° C for 20 hours. The mixture is cooled, the precipitate is filtered and recrystallized from ethanol and then from hexane / chloroform.
Yield 0.5 g (64%), m.p. 141-144 ° C.
PRI me R 4. Ethyl ester of 4- (2-methoxyphenyl) -thiazole-2-oxamic acid.
A suspension of 2 g of 4- (2-methoxyphenyl) -thiazole-2-oxamic acid ethyl ester in 30 ml of 1N sodium hydroxide is heated with vigorous stirring until a clear solution is obtained. By acidification with 2N hydrochloric acid, a precipitate is obtained which, after cooling the mixture and diluting with water, is filtered off. The residue is vortexed twice with water (100 ml), filtered and washed with ethanol. The acid is purified by recrystallization of dimethylformamide / ethanol. Yield 1 g (55%), t.sh .. 195-197 ° C.
Compounds of formula I obtained in Table 1 are prepared analogously.
The compounds of the formula I or their salts have an anti-allergic effect. With respect to an anti-allergic agent, such as 1,3-bis- (2-carboxychromon-5-yloxy) -2-hydroxypropane, is well known to the oral anti-allergic agent. In addition, the inhibitory effect on allergic reactions occurs at a much lower dosage and lasts longer.
Antiallergic action was determined on rats in the so-called PKA test (passive skin anaphylaxis test). At the same time, rat skin is sensitized by intradermal injection of the albumin-antisera of various dilutions (undiluted and diluted 1: 3, D: 9, 1:27, etc.). The next day, the animals were injected intravenously with albumin in a blue solution of Evens.
PKA titer was determined by measuring the degree of blue. The compounds to be tested in various concentrations were intravenously or orally administered together with the blue solution of Even. ca. Each rat was administered 5 mg of egg albumin dissolved in 1 ml of 0.25% Even dye in sterile saline.
25-30 minutes after dye and test substance are administered.
animals are sacrificed and the blue of the inner surface of the skin is measured in mm. A PKA titer is the inverse of that time: serum pressure, at which it is possible to determine blue in diameter, at least 5 mm. The reduction of PKA titer is a measure for inhibiting allergic reactions, in this case against egg albumin.
20B table. 2 shows oral or
intravenous antiallergic action of some compounds of the formula I or their salts.
Compounds of formula 1 and their salts
25 is used in the treatment of allergic asthma, hay fever, urticaria, bzema, atopic dermatitis and other allergic diseases.
For therapeutic purposes, 30pl of the compounds of formula 1 can be mixed with common pharmaceutical excipients or carriers, gelling, binding, lubricating agents, thickening agents or diluents, solvents or agents to achieve a prolonged effect, which can be used enterally, and parenteral.
40
As pharmaceutical preparations, for example, tablets, dragees, pills, capsules, solutions, suspensions, ointments, powders, tinctures, solutions for injection or aerosols are suitable, and in addition to the compounds of the formula 1, preservatives or stabilizers, emulsifiers, buffering agents and etc.
Efv Pharmaceutical preparations for parenteral administration and for inhalation are generally 5-50 mg per dose and in oral administration of 50-500 mg.
Table 1
JW "4-CO-COOV
15
axis.
sixteen
CHjC
133-136
Ca "S
203-207
Happy birthday
BUT
eo-cho;
28
CHjO
Continued table. one
247-250
164-168
167-170
S "5
189-195
Cl
210-213
Ca "S
141-144
HS
Ho
C3, Hj173-176
Continued table. one
CHjO
42
% ° -HOW
(
43
44
45
, 47
Continued table. one
185-187
170-174
CH.
186-190
(ethanolamine salt)
147-150
(ethanolamine salt)
S "5
167-170
sn. 230-233 (ethanolamine salt)
CH, BUT
48
212-215

49
215-219
(ethanolamine salt)
50207-208
(ethanolamine salt)
%
51
™ -cho:
203-206
(ethanolamine salt)
52
164-167
SaNu
53
167-176
(ethanol new salt)
Continued table. one
54
220-223
Sa.H5
55
195-197
(ethanolamine
salt)
56
197-199 (ethanolamine
Compound
4-phenyl-5-methyl-thiazole-2-oxamic acid, ethanolamine salt
4- (3-dimethylaminophenyl) -thiazole-2oxamic acid, ethanolamine salt
4- (2, 4-dimethoxyphenyl) -thiaole-2-oxamic acid
4- (2, 5 - dimethoxyphenyl) -thiazole-2-oxamog. 1I acid, ethanolamine salt
4- (2-methoxyphenyl) -thiazole-2-oxamic acid
one.
ED50.ED50,
mg / kg oral g / kg oral
2.04
1.6
Sales table. 2
4- (pyridyl- (A)) - thiao-2-oxamic acid ethyl ester
methyl 4- (3, 4-dimethoxyphenyl) -thiazole-2-oxamic acid
4- (4-ethoxyphenyl) -thiazole-2-oxamic acid ethyl ester
4- (3-methyl-4foxyphenyl) -thiazole-2-oxamic acid ethyl ester

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining derivatives of thiazole-2-oxamic acid of General formula 120
SH-CO-COOR
the fact that, in order to obtain new compounds that expand the arsenal of means of influence on a living organism, 2-silynothiazole of the general formula 11
NH.
and
but
25

类似技术:

公开号 | 公开日 | 专利标题

SU791237A3|1980-12-23|Method of preparing derivatives of thiazole-2-oxamic acid or their salts

CN102137592B|2015-01-28|Compounds for the treatment of cancer

KR100456177B1|2004-12-30|N-benzyl dioxothiazolyldibenzamide derivatives and processes for their preparation

KR20030097596A|2003-12-31|Substituted Thiazolidinedione Derivatives

EP0262873B1|1991-08-21|N-tetrazolyl thiazolecarboxamide derivatives and their use

FI63573C|1985-05-15|FREEZING FOR OXIBENSOTIAZINE DIOXIDERS CABOXAMIDERS

KR20210089195A|2021-07-15|Biphenyl-based compounds, intermediates thereof, preparation methods, pharmaceutical compositions and uses

IL144229A|2006-10-05|Novel 2-| thiazolidin-4-one derivatives

EP0321115B1|1991-08-14|Carboxamide derivatives having tetrazole and thiazole rings and their use

KR900006118B1|1990-08-22|Process for preparing 4-quinolone derivatives

PL84190B1|1976-03-31|3-aroyl-alkenyleneimines[us3835149a]

KR100295717B1|2001-11-05|2-Cyano-3-hydroxy-propenamide, a process for its preparation, pharmaceutical compositions containing it and uses thereof as medicaments

JPH0649047A|1994-02-22|New phenylcarboxamidoisoxazole derivative and its salt, their production, new intermediate for producing them, their use as drug, and drug composition containing them

KR930006776B1|1993-07-23|Process for the preparation of substituted isoxazole derivatives

IL31915A|1972-10-29|Thiazolines,their preparation and pharmaceutical compositions containing them

US4680405A|1987-07-14|Process for preparing 2-[|methyl]saccharin

Wright et al.1977| oxamic acids and | oxamic acids as antiallergy agents

FI62531C|1983-01-10|PROCEDURE FOR THE FRAMSTATION OF THE THERAPEUTIC SYSTEM 3-YAN-N- | -IMINODIBENSYL OCH SYRAADD ITONSSALTER DAERAV

JP2963496B2|1999-10-18|Benzopyranopyridine derivative

US5468761A|1995-11-21|4-methyl-5-substituted-1,3-oxazoles having anti-inflammatory activity

US4902688A|1990-02-20|4-|-thiazole-derivatives with anti-allergic, anti-anaphylactic and anti-arthritic activity and compositions containing them

US4755506A|1988-07-05|Pharmaceutical compositions of [|diimino]bisbenzoic acid derivatives and their use

KR920008822B1|1992-10-09|Process for preparation of new esters derived from 4-hydroxy 3-quinoline carboxylic acid substituted by an alpha-hydroxyl chain at position 2

US4829077A|1989-05-09|Benzopyran[4,3-d]-thiazole-derivatives with anti-allergic, anti-anaphylactic and anti-arithritic activity and compositions containing them

US5292751A|1994-03-08|5,7-dihydroxy-2-methyl-8-|)piperidinyl)-4H-1-benzopyran-4-one, its preparation and its use

同族专利:

公开号 | 公开日

US4238496A|1980-12-09|

CS208114B2|1981-08-31|

JPS6356225B2|1988-11-07|

SE446182B|1986-08-18|

BE877293A|1979-12-27|

DE2828091A1|1980-01-10|

CA1246071A|1988-12-06|

DK147940B|1985-01-14|

FR2429787A1|1980-01-25|

AU525312B2|1982-10-28|

MY8600653A|1986-12-31|

DK269879A|1979-12-28|

NL7904957A|1980-01-02|

PL117333B1|1981-07-31|

AU4839779A|1980-01-03|

YU149779A|1982-10-31|

IT7949533D0|1979-06-25|

CH644370A5|1984-07-31|

NZ190842A|1981-01-23|

FI792006A|1979-12-28|

GB2023580A|1980-01-03|

NO792139L|1979-12-28|

PT69822A|1979-07-01|

NO151500B|1985-01-07|

LU81424A1|1980-07-21|

DE2828091C2|1988-05-26|

ZA793176B|1981-03-25|

NO151500C|1985-04-24|

FI69456B|1985-10-31|

ATA431879A|1983-07-15|

RO77553A|1982-02-01|

IE48357B1|1984-12-26|

DD144542A5|1980-10-22|

IT1120443B|1986-03-26|

DK147940C|1985-09-02|

SE7905608L|1979-12-28|

FI69456C|1986-02-10|

GR69231B|1982-05-10|

IE791200L|1979-12-27|

HK66285A|1985-09-13|

AT373884B|1984-02-27|

ES481917A1|1980-02-16|

SG61985G|1986-05-02|

BG30324A3|1981-05-15|

IL57659D0|1979-10-31|

JPS557290A|1980-01-19|

PL216608A1|1980-03-24|

GB2023580B|1982-08-25|

YU41645B|1987-12-31|

HU178996B|1982-07-28|

FR2429787B1|1982-12-31|

PH17226A|1984-07-03|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

DE1062245B|1957-10-17|1959-07-30|Ciba Geigy|Process for the preparation of 2-amino-4-pyridyl- -thiazole and its salts|

FR1526074A|1967-03-22|1968-05-24|Rech S Ind S O R I Soc D|Methoxy-phenyl-amino-2-thiazoles, their amides and processes for their preparation|

BE795907A|1972-02-25|1973-06-18|Luso Farmaco Inst|2-AMINO-4-ARYLTHIAZOLES 5-SUBSTITUTES AND THEIR PREPARATION|

US4054666A|1973-03-23|1977-10-18|American Home Products Corporation|Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives|

US3966965A|1973-03-23|1976-06-29|American Home Products Corporation|Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions|

FR2429210B1|1978-06-19|1980-10-31|Fabre Sa Pierre|US4321372A|1980-06-16|1982-03-23|Pfizer Inc.|Antiulcer thiazol-2-ylcarbamoyl-carboxylic acids, esters and amides|

DE3027528A1|1980-07-19|1982-02-18|Basf Ag, 6700 Ludwigshafen|BRIDGED THIAZOLYLOXAMID ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC AGENTS CONTAINING THEM|

DE3027527A1|1980-07-19|1982-02-18|Basf Ag, 6700 Ludwigshafen|NEW OXAMID ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC AGENTS CONTAINING THEM|

FR2494272B1|1980-11-19|1982-12-03|Fabre Sa Pierre|

DE3135250A1|1981-09-05|1983-03-17|Basf Ag, 6700 Ludwigshafen|TRICYCLIC THIAZOLYLOXAMATES, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC AGENTS CONTAINING THEM|

US4788198A|1983-09-01|1988-11-29|Boehringer Ingelheim Pharmaceuticals, Inc.|Diazine-ethyenylphenyl oxamic acids and esters and salts thereof|

EP0137979B1|1983-09-01|1988-10-26|Boehringer Ingelheim Pharmaceuticals Inc.|Diazine-ethenylphenyl oxamic acids and esters and salts thereof|

US4681884A|1983-09-01|1987-07-21|Boehringer Ingelheim Pharmaceuticals, Inc.|Diazine-ethenylphenyl oxamic acids and esters and salts thereof|

IT1204960B|1987-03-25|1989-03-10|Zambon Farmaceutici Spa|COMPOUNDS EQUIPPED WITH ANTIALLERGIC ACTIVITY|

IT1204959B|1987-03-25|1989-03-10|Zambon Farmaceutici Spa|COMPOUNDS EQUIPPED WITH ANTIALLERGIC ACTIVITY|

DE3807232A1|1988-03-05|1989-09-14|Bayer Ag|SUBSTITUTED ACRYLIC ACID ESTERS|

FR2671552B1|1991-01-15|1993-05-07|Pf Medicament|PROCESS FOR THE PREPARATION OF ALKYL OXAMATE THIAZOLYL-2.|

CA2302417A1|1997-10-27|1999-05-06|Takeda Chemical Industries, Ltd.|Adenosine a3 receptor antagonists|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

DE2828091A|DE2828091C2|1978-06-27|1978-06-27|

[返回顶部]